[go: up one dir, main page]

AR060424A1 - Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento - Google Patents

Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento

Info

Publication number
AR060424A1
AR060424A1 ARP070101520A ARP070101520A AR060424A1 AR 060424 A1 AR060424 A1 AR 060424A1 AR P070101520 A ARP070101520 A AR P070101520A AR P070101520 A ARP070101520 A AR P070101520A AR 060424 A1 AR060424 A1 AR 060424A1
Authority
AR
Argentina
Prior art keywords
compositions
treatment
mel
microorganisms
deposited
Prior art date
Application number
ARP070101520A
Other languages
English (en)
Inventor
Euw Erika Maria Von
Jose Mordoh
Maria Marcela Barrio
Original Assignee
Consejo Nac Invest Cient Tec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nac Invest Cient Tec filed Critical Consejo Nac Invest Cient Tec
Priority to ARP070101520A priority Critical patent/AR060424A1/es
Priority to DK08737810.5T priority patent/DK2146742T3/da
Priority to RU2009141593/10A priority patent/RU2484134C2/ru
Priority to KR1020097022846A priority patent/KR101502518B1/ko
Priority to MX2009010927A priority patent/MX2009010927A/es
Priority to AU2008238909A priority patent/AU2008238909B2/en
Priority to PCT/IB2008/051385 priority patent/WO2008126039A2/es
Priority to EP08737810A priority patent/EP2146742B1/en
Priority to ES08737810T priority patent/ES2390130T3/es
Priority to BRPI0809767-4A priority patent/BRPI0809767B1/pt
Priority to JP2010502629A priority patent/JP5762738B2/ja
Priority to US12/450,721 priority patent/US8501168B2/en
Priority to CN2008800182498A priority patent/CN101861163B/zh
Priority to NZ580533A priority patent/NZ580533A/xx
Priority to CA2683629A priority patent/CA2683629C/en
Publication of AR060424A1 publication Critical patent/AR060424A1/es
Priority to ZA200907240A priority patent/ZA200907240B/xx
Priority to CO09121156A priority patent/CO6260100A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Líneas celulares, composiciones para el tratamiento de melanomas que las comprenden, procedimientos para preparar las composiciones y métodos de tratamiento. Más particularmente la presente se refiere a varias líneas celulares de melanoma humano para el tratamiento de enfermedades malignas, en donde las líneas celulares son: (a) Mel-XY1 (depositada en German Collection of Microorganisms and CelI Cultures DSMZ bajo el numero de acceso DSM ACC2830), (b) Mel-XY2 (depositada en German Collection of Microorganisms and Cell Cultures DSMZ bajo el numero de acceso DSM ACC2831), (c) Mel-XY3 (depositada en German Collection of Microorganisms and CelI Cultures DSMZ bajo el numero de acceso DSM ACC2832), (d) Mel-XX4 (depositada en German Collection of Microorganisms and CelI Cultures DSMZ bajo el numero de acceso DSM ACC2829) o (e) sub-poblaciones de las mismas. Las líneas celulares pueden ser irradiadas obteniéndose poblaciones con fenotipo apoptotico y poblaciones con fenotipo necrotico de dichas líneas. Las composiciones pueden comprender adyuvantes y/o inmunomodificadores y/o células dendríticas autologas.
ARP070101520A 2007-04-11 2007-04-11 Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento AR060424A1 (es)

Priority Applications (17)

Application Number Priority Date Filing Date Title
ARP070101520A AR060424A1 (es) 2007-04-11 2007-04-11 Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
EP08737810A EP2146742B1 (en) 2007-04-11 2008-04-11 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
JP2010502629A JP5762738B2 (ja) 2007-04-11 2008-04-11 細胞株、黒色腫の治療のためにそれを含む組成物、組成物の製造手順および治療方法
KR1020097022846A KR101502518B1 (ko) 2007-04-11 2008-04-11 세포주, 이를 포함하는 흑색종의 치료를 위한 조성물, 조성물 제조방법 및 치료방법
MX2009010927A MX2009010927A (es) 2007-04-11 2008-04-11 Lineas celulares, composiciones para el tratamiento de melanomas que las comprenden, procedimientos para preparar las composiciones, y metodos de tratamiento.
AU2008238909A AU2008238909B2 (en) 2007-04-11 2008-04-11 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
PCT/IB2008/051385 WO2008126039A2 (es) 2007-04-11 2008-04-11 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
DK08737810.5T DK2146742T3 (da) 2007-04-11 2008-04-11 Cellelinjer, sammensætninger omfattende disse til behandling af melanomer, fremgangsmåder til at fremstille sammensætningerne og behandlingsmetoder
ES08737810T ES2390130T3 (es) 2007-04-11 2008-04-11 Líneas celulares, composiciones que las comprenden para el tratamiento de los melanomas, procedimientos para preparar las composiciones y métodos de tratamiento
BRPI0809767-4A BRPI0809767B1 (pt) 2007-04-11 2008-04-11 Composição para o tratamento do melanoma, composição para o tratamento de melanomas humanos, procedimento para preparação da composição e procedimento para preparar a composição para tratamento de melanomas humanos
RU2009141593/10A RU2484134C2 (ru) 2007-04-11 2008-04-11 Клеточные линии, содержащие их композиции для лечения меланом, способы получения композиций и способы лечения
US12/450,721 US8501168B2 (en) 2007-04-11 2008-04-11 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
CN2008800182498A CN101861163B (zh) 2007-04-11 2008-04-11 用于治疗黑素瘤的细胞系、含有它们的组合物、制备所述组合物的方法以及治疗方法
NZ580533A NZ580533A (en) 2007-04-11 2008-04-11 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
CA2683629A CA2683629C (en) 2007-04-11 2008-04-11 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
ZA200907240A ZA200907240B (en) 2007-04-11 2009-10-16 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
CO09121156A CO6260100A2 (es) 2007-04-11 2009-10-28 Lineas celulares composiciones pera el tratamiento de melanomas que las comprenden procedimiento para preparar las composiciones y metodos de tratamiento

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP070101520A AR060424A1 (es) 2007-04-11 2007-04-11 Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento

Publications (1)

Publication Number Publication Date
AR060424A1 true AR060424A1 (es) 2008-06-18

Family

ID=39590605

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101520A AR060424A1 (es) 2007-04-11 2007-04-11 Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento

Country Status (17)

Country Link
US (1) US8501168B2 (es)
EP (1) EP2146742B1 (es)
JP (1) JP5762738B2 (es)
KR (1) KR101502518B1 (es)
CN (1) CN101861163B (es)
AR (1) AR060424A1 (es)
AU (1) AU2008238909B2 (es)
BR (1) BRPI0809767B1 (es)
CA (1) CA2683629C (es)
CO (1) CO6260100A2 (es)
DK (1) DK2146742T3 (es)
ES (1) ES2390130T3 (es)
MX (1) MX2009010927A (es)
NZ (1) NZ580533A (es)
RU (1) RU2484134C2 (es)
WO (1) WO2008126039A2 (es)
ZA (1) ZA200907240B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6077735B2 (ja) * 2011-06-08 2017-02-08 日本電子株式会社 電子顕微鏡観察用染色剤および電子顕微鏡観察用試料の染色方法
SG11201401632WA (en) 2011-10-20 2014-05-29 California Stem Cell Inc Antigen presenting cancer vaccine
JP6077757B2 (ja) * 2012-04-17 2017-02-08 日本電子株式会社 電子顕微鏡観察用染色剤および電子顕微鏡観察用試料の染色方法
JP5921386B2 (ja) * 2012-08-27 2016-05-24 日本電子株式会社 電子顕微鏡観察用染色剤および電子顕微鏡観察用試料の染色方法
CN103146641B (zh) * 2013-02-06 2015-03-25 云南中科灵长类生物医学重点实验室 多能干细胞的传代方法及其用途
CN104990781B (zh) * 2015-06-29 2018-02-16 中国医学科学院皮肤病研究所 黑素细胞免疫组化苏木素—甲苯胺蓝双重复染法
JP2023504659A (ja) 2019-12-03 2023-02-06 ニューボーゲン，インコーポレイティド 腫瘍細胞ワクチン
RU2755233C1 (ru) * 2021-01-11 2021-09-14 Сергей Анатольевич Яргунин Способ лечения меланомы кожи IIb-IIc стадий
CN115074328B (zh) * 2022-06-21 2025-02-07 中国人民解放军空军军医大学 一种用于治疗黑素瘤的细胞株及其多效价全细胞疫苗与使用方法
WO2025224605A1 (en) 2024-04-23 2025-10-30 Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet) Sequential administration of anti-melanoma vaccine and anti-pd-1 monoclonal antibodies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882654A (en) * 1989-11-03 1999-03-16 Morton; Donald L. Polyvalent melanoma vaccine
IL127912A0 (en) * 1996-07-10 1999-11-30 Immunex Corp Method of activating dendritic cells
AU3889997A (en) * 1996-08-16 1998-03-06 Johns Hopkins University School Of Medicine, The Melanoma cell lines expressing shared immunodominant melanoma antigens nd methods of using same
US6602709B1 (en) * 1998-02-20 2003-08-05 The Rockefeller University Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells
WO2001029192A2 (en) * 1999-10-15 2001-04-26 Baylor Research Institute Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
WO2001028583A2 (en) * 1999-10-18 2001-04-26 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
EP1254953A4 (en) * 1999-12-28 2004-06-02 Toyoshima Kumao Maturity-triggering agent for immature dendritic cells
ES2292619T3 (es) * 2000-09-15 2008-03-16 Ortho-Mcneil Pharmaceutical, Inc. Composiciones y metodos para inducir respuestas citologicas especificas de la celula t.
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
IL140796A0 (en) * 2001-01-08 2002-02-10 Hadasit Med Res Service An autologous anti-cancer vaccine
US20040087532A1 (en) * 2001-03-09 2004-05-06 Banchereau Jacques F. Method of treating malignancies through induction of blood immune responses
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
EP1451305A4 (en) * 2001-11-07 2005-10-05 Mannkind Corp EPITOPE SYNCHRONIZATION IN CELLS THAT HAVE ANTIGENS
PL377209A1 (pl) * 2002-12-06 2006-01-23 Northwest Biotherapeutics, Inc. Leczenie nowotworów poprzez podawanie pacjentom częściowo dojrzałych in vitro komórek dendrytycznych
CN101052726A (zh) * 2003-05-09 2007-10-10 森托科尔公司 IL－23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途
EP1682159A4 (en) * 2003-10-16 2010-07-21 Stephen John Ralph IMMUNOMODULATING COMPOSITIONS AND THEIR USES
RU2262941C2 (ru) 2004-01-05 2005-10-27 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ иммунотерапии злокачественных опухолей головного мозга
JP5848861B2 (ja) * 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
MXPA06012601A (es) * 2004-05-10 2007-05-10 Macrogenics Inc Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
RU2283129C1 (ru) 2004-12-24 2006-09-10 Сергей Викторович Луценко Белковопептидный противоопухолевый композит, клеточный препарат, активированный этим композитом, и способ профилактики или лечения опухолей

Also Published As

Publication number Publication date
ZA200907240B (en) 2010-07-28
MX2009010927A (es) 2010-02-11
CA2683629A1 (en) 2008-10-23
EP2146742A2 (en) 2010-01-27
JP5762738B2 (ja) 2015-08-12
CN101861163B (zh) 2013-06-12
AU2008238909B2 (en) 2013-11-07
WO2008126039A2 (es) 2008-10-23
US8501168B2 (en) 2013-08-06
CO6260100A2 (es) 2011-03-22
AU2008238909A1 (en) 2008-10-23
ES2390130T3 (es) 2012-11-06
RU2009141593A (ru) 2011-05-20
BRPI0809767A2 (pt) 2014-09-23
KR20090129501A (ko) 2009-12-16
RU2484134C2 (ru) 2013-06-10
KR101502518B1 (ko) 2015-03-13
CA2683629C (en) 2016-06-21
WO2008126039A3 (es) 2008-12-11
US20100183683A1 (en) 2010-07-22
NZ580533A (en) 2012-08-31
BRPI0809767B1 (pt) 2022-04-12
CN101861163A (zh) 2010-10-13
JP2010523141A (ja) 2010-07-15
EP2146742B1 (en) 2012-07-11
DK2146742T3 (da) 2012-10-22

Similar Documents

Publication Publication Date Title
AR060424A1 (es) Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
MY159971A (en) Multipotent/pluripotent cells and methods
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
MX2009014273A (es) Metodos y composiciones para expansion e implantacion optimizadas de celulas madre mesenquimales.
MX2021000607A (es) Células t con receptor de antígeno quimérico derivadas de células madre pluripotentes inmunomodificadas.
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
AR080030A1 (es) Tratamiento de tipos de cancer oseo mediante el uso de celulas madre placentarias
MX2016013747A (es) Métodos para aislar, cultivar y diseñar genéticamente poblaciones de células inmunes para terapia adoptiva.
MX2013010793A (es) Metodo y composiciones para inmunoterapia celular.
NZ593364A (en) Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
Devitt et al. Successful isolation of viable adipose‐derived stem cells from human adipose tissue subject to long‐term cryopreservation: positive implications for adult stem cell‐based therapeutics in patients of advanced age
GB2434157A (en) Platelets from stem cells
BR112014032074A2 (pt) construções de tecido conjuntivo tridimensionais engendradas e métodos de fabricar as mesmas
MX2019015321A (es) Composiciones tridimensionales de tejido y métodos de uso.
EP3257943A3 (en) Methods and vectors for cell immortalisation
AR080816A1 (es) Preparacion derivada de un cultivo in vitro de celulas de argan no evocadas desdiferenciadas, su uso para el tratamiento del envejecimiento, la inflamacion y curacion de la piel, y metodo para su obtencion
MX339068B (es) Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
WO2015154012A8 (en) Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
PH12013501773A1 (en) Nutritional compositions for increasing arginine levels and methods of using same
BR112012019190A2 (pt) composições de cuidado oral.
CO6761392A2 (es) Administración de proteínas a partir de microportadores de células madre
MX337480B (es) Celulas madre del revestimiento de cordon umbilical y metodos y material para aislar y cultivar las mismas.
BR112022004562A2 (pt) Método de seleção de doador universal para identificar doadores de células nk
CL2010000774A1 (es) Medio para el cultivo de celulas de mamiferos que comprende ademas de los nutrientes habituales de los medios de cultivo basales para cultivo de celulas de mamiferos, sobrenadante de la fraccion ii+iii del plasma humano segun el metodo de cohn; procedimiento de preparacion; y su uso.
WO2015181831A3 (en) A method for targettingglioblastoma with wharton jelly-mesenchymal stem cells (wj-msc) derived from human umbilical cord

Legal Events

Date Code Title Description
FG Grant, registration